**SUPPLEMENTARY DATA**

**Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study**

**Authors:** Dan Ilges1, Dylan Kosaski2, Maria Teresa Seville3, Alyssa K. McGary4, John C. O’Horo5,6, Christine L. Snozek7, Ryan W. Stevens2, Aditya Shah5

**Affiliations:**

1. Department of Pharmacy Services, Mayo Clinic Arizona, Phoenix, AZ, USA
2. Department of Pharmacy Services, Mayo Clinic, Rochester, MN, USA
3. Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ, USA
4. Division of Clinical Trials and Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, USA
5. Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA
6. Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, USA
7. Division of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA

**Corresponding author:**

Dan Ilges, PharmD

Department of Pharmacy Services

Mayo Clinic Arizona

5777 E Mayo Blvd.

Phoenix, AZ 85054

Ilges.daniel@mayo.edu

**Supplementary Table 1: ICD-10 Codes for Pneumonia Diagnosis in the Overall and Matched Cohorts**

| **Diagnosis Code** | **Overall Cohort** | **Matched Cohort** |
| --- | --- | --- |
| **No (N=8849)** | **Yes (N=6515)** | **No (N=6440)** | **Yes (N=6440)** |
| A37.01 | 1 (0%) | 0 (0%) | 1 (0%) | 0 (0%) |
| A37.81 | 0 (0%) | 1 (0%) | 0 (0%) | 1 (0%) |
| A37.91 | 0 (0%) | 1 (0%) | 0 (0%) | 1 (0%) |
| A48.1 | 54 (0.6%) | 46 (0.7%) | 36 (0.6%) | 46 (0.7%) |
| B01.2 | 3 (0%) | 0 (0%) | 3 (0%) | 0 (0%) |
| J09.X1 | 7 (0.1%) | 5 (0.1%) | 6 (0.1%) | 5 (0.1%) |
| J10.00 | 70 (0.8%) | 55 (0.8%) | 53 (0.8%) | 53 (0.8%) |
| J10.08 | 102 (1.2%) | 91 (1.4%) | 72 (1.1%) | 90 (1.4%) |
| J11.00 | 7 (0.1%) | 2 (0%) | 6 (0.1%) | 2 (0%) |
| J11.08 | 9 (0.1%) | 9 (0.1%) | 4 (0.1%) | 9 (0.1%) |
| J12.0 | 3 (0%) | 7 (0.1%) | 3 (0%) | 7 (0.1%) |
| J12.1 | 95 (1.1%) | 87 (1.3%) | 70 (1.1%) | 87 (1.4%) |
| J12.2 | 30 (0.3%) | 24 (0.4%) | 20 (0.3%) | 23 (0.4%) |
| J12.3 | 50 (0.6%) | 59 (0.9%) | 36 (0.6%) | 58 (0.9%) |
| J12.81 | 2 (0%) | 0 (0%) | 1 (0%) | 0 (0%) |
| J12.82 | 1 (0%) | 0 (0%) | 1 (0%) | 0 (0%) |
| J12.89 | 65 (0.7%) | 73 (1.1%) | 47 (0.7%) | 71 (1.1%) |
| J12.9 | 66 (0.7%) | 91 (1.4%) | 52 (0.8%) | 91 (1.4%) |
| J13 | 149 (1.7%) | 125 (1.9%) | 110 (1.7%) | 124 (1.9%) |
| J14 | 43 (0.5%) | 31 (0.5%) | 30 (0.5%) | 31 (0.5%) |
| J15.0 | 63 (0.7%) | 53 (0.8%) | 42 (0.7%) | 53 (0.8%) |
| J15.1 | 177 (2%) | 161 (2.5%) | 142 (2.2%) | 160 (2.5%) |
| J15.20 | 22 (0.2%) | 13 (0.2%) | 14 (0.2%) | 12 (0.2%) |
| J15.211 | 109 (1.2%) | 83 (1.3%) | 74 (1.1%) | 81 (1.3%) |
| J15.212 | 86 (1%) | 74 (1.1%) | 73 (1.1%) | 74 (1.1%) |
| J15.29 | 4 (0%) | 2 (0%) | 2 (0%) | 2 (0%) |
| J15.3 | 5 (0.1%) | 5 (0.1%) | 0 (0%) | 5 (0.1%) |
| J15.4 | 47 (0.5%) | 43 (0.7%) | 30 (0.5%) | 41 (0.6%) |
| J15.5 | 31 (0.4%) | 34 (0.5%) | 19 (0.3%) | 32 (0.5%) |
| J15.6 | 321 (3.6%) | 246 (3.8%) | 234 (3.6%) | 244 (3.8%) |
| J15.7 | 26 (0.3%) | 47 (0.7%) | 19 (0.3%) | 46 (0.7%) |
| J15.8 | 120 (1.4%) | 75 (1.2%) | 83 (1.3%) | 75 (1.2%) |
| J15.9 | 1393 (15.7%) | 1077 (16.5%) | 1003 (15.6%) | 1065 (16.5%) |
| J16.0 | 7 (0.1%) | 4 (0.1%) | 6 (0.1%) | 4 (0.1%) |
| J16.8 | 24 (0.3%) | 21 (0.3%) | 19 (0.3%) | 21 (0.3%) |
| J17 | 6 (0.1%) | 1 (0%) | 5 (0.1%) | 1 (0%) |
| J18.0 | 101 (1.1%) | 84 (1.3%) | 73 (1.1%) | 83 (1.3%) |
| J18.1 | 315 (3.6%) | 219 (3.4%) | 235 (3.6%) | 216 (3.4%) |
| J18.8 | 67 (0.8%) | 42 (0.6%) | 41 (0.6%) | 40 (0.6%) |
| J18.9 | 3922 (44.3%) | 2827 (43.4%) | 2820 (43.8%) | 2803 (43.5%) |
| J69.0 | 2200 (24.9%) | 1577 (24.2%) | 1640 (25.5%) | 1553 (24.1%) |
| J84.116 | 15 (0.2%) | 31 (0.5%) | 8 (0.1%) | 31 (0.5%) |
| J85.1 | 102 (1.2%) | 41 (0.6%) | 75 (1.2%) | 41 (0.6%) |

**Supplementary Table 2: Matching Variables in Overall and Matched Cohorts**

| **Matching variable** | **Overall Cohort** | **Matched Cohort** |
| --- | --- | --- |
| **No PCT (N=8849)** | **PCT (N=6515)** | **Standard Difference** | **No PCT (N=6440)** | **PCT (N=6440)** | **Standard Difference** |
| **Age** |  |  |  |  |  |  |
|    18-34 | 390 (4.4%) | 295 (4.5%) | 0.006 | 263 (4.1%) | 263 (4.1%) | 0 |
|    35-64 | 2524 (28.5%) | 1787 (27.4%) | -0.025 | 1781 (27.7%) | 1781 (27.7%) | 0 |
|    65-79 | 3390 (38.3%) | 2523 (38.7%) | 0.009 | 2502 (38.9%) | 2502 (38.9%) | 0 |
|    ≥80 | 2545 (28.8%) | 1910 (29.3%) | 0.012 | 1894 (29.4%) | 1894 (29.4%) | 0 |
| **ICU Admission** |  |  |  |  |  |  |
|    No | 6829 (77.2%) | 5076 (77.9%) | 0.018 | 5042 (78.3%) | 5042 (78.3%) | 0 |
|    Yes | 2020 (22.8%) | 1439 (22.1%) | -0.018 | 1398 (21.7%) | 1398 (21.7%) | 0 |
| **CCI** |  |  |  |  |  |  |
|    0 | 506 (5.7%) | 402 (6.2%) | 0.019 | 384 (6.0%) | 384 (6.0%) | 0 |
|    1-3 | 2502 (28.3%) | 1824 (28.0%) | -0.006 | 1824 (28.3%) | 1824 (28.3%) | 0 |
|    4-6 | 2267 (25.6%) | 1696 (26.0%) | 0.009 | 1682 (26.1%) | 1682 (26.1%) | 0 |
|    7-9 | 1785 (20.2%) | 1334 (20.5%) | 0.008 | 1318 (20.5%) | 1318 (20.5%) | 0 |
|    10-12 | 1165 (13.2%) | 827 (12.7%) | -0.014 | 817 (12.7%) | 817 (12.7%) | 0 |
|    13-15 | 435 (4.9%) | 293 (4.5%) | -0.02 | 284 (4.4%) | 284 (4.4%) | 0 |
|    >15 | 189 (2.1%) | 139 (2.1%) | 0 | 131 (2.0%) | 131 (2.0%) | 0 |
| **Year** |  |  |  |  |  |  |
|    2018-2019 | 2731 (30.9%) | 2256 (34.6%) | 0.079 | 2220 (34.5%) | 2220 (34.5%) | 0 |
|    2020-2021 | 3581 (40.5%) | 2422 (37.2%) | -0.068 | 2413 (37.5%) | 2413 (37.5%) | 0 |
|    2022-2023 | 2537 (28.7%) | 1837 (28.2%) | -0.011 | 1807 (28.1%) | 1807 (28.1%) | 0 |

**Supplementary Table 3: Overall Average Treatment Duration by Region**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Region** | ARZ (N=3227) | FLA (N=2882) | NWWI (N=1724) | RST (N=3528) | SEMN (N=1424) | SWMN (N=1655) | SWWI (N=924) |
| **Mean Treatment Duration, days** | 5.0 (3.9) | 5.3 (4.6) | 4.7 (2.6) | 4.6 (3.4) | 4.1 (1.9) | 4.7 (2.8) | 4.4 (2.7) |

**Supplementary Table 4: Outcomes Among Patients with Abnormal Procalcitonin Compared to Patients with Normal Procalcitonin in the Overall Cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | PCT ≥0.25 (N=3217) | PCT <0.25 (N=3298) | p value |
| **Treatment Duration** | 5.5 (4.1) | 4.7 (3.5) | <0.001 |
| **Days of Therapy** | 9.3 (6.8) | 7.9 (5.9) | <0.001 |
| **Length of stay (days)** | 7.6 (9.6) | 6.0 (7.5) | <0.001 |
| **Cumulative ASI** | 52.2 (42.7) | 43.4 (36.8) | < 0.001 |
| **Number of CT Chest Scans** | 0.4 (0.5) | 0.3 (0.5) | < 0.001 |
| **30-day all-cause mortality** | 459 (14%) | 237 (7%) | < 0.001 |
| ***C. difficile* within 90 days of index admission** | 13 (0%) | 10 (0%) | 0.536 |

Results are shown as mean (standard deviation) or number (%) unless otherwise noted.

**Supplementary Table 5: Outcomes Among Patients without Procalcitonin Compared to Patients with Abnormal Procalcitonin in the Overall Cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| Outcome | No PCT (N=8849) | PCT ≥0.25 (N=3217) | p value |
| **Patient Antibiotic Days** | 4.6 (3.2) | 5.5 (4.1) | <0.001 |
| **Days of Therapy** | 7.6 (5.7) | 9.3 (6.8) | <0.001 |
| **Length of stay (days)** | 5.9 (6.9) | 7.6 (9.6) | <0.001 |
| **Cumulative ASI** | 41.2 (34.2) | 52.2 (42.7) | < 0.001 |
| **Number of CT Chest Scans** | 0.2 (0.5) | 0.4 (0.5) | < 0.001 |
| **30-day all-cause mortality** | 968 (11%) | 459 (14%) | < 0.001 |
| ***C. difficile* within 90 days of index admission** | 38 (0%) | 13 (0%) | 0.416 |

Results are shown as mean (standard deviation) or number (%) unless otherwise noted.